METHODS: Formalin-fixed paraffin embedded (FFPE) primary prostate cancer samples were obtained from the Welsh Cancer Bank. Targeted-NGS was performed using the Life Technologies Ion Torrent: Ion AmpliSeq Cancer Hotspot Panel v2 and the Ion Personal Genome Machine sequencer. The hotspot panel covers~2800 COSMIC mutations of 50 oncogenes and tumour suppressor genes. Standard IHC techniques were also used concentrating on markers of the Wnt, PI3-Kinase (PI3K) and MAP-Kinase (MAPK) oncogenic signalling pathways.
RESULTS: 61 primary prostate cancer samples were sequenced, 58 from radical retropubic prostatectomy (RRP) specimens and 3 from transurethral resection of prostate (TURP) sections, with a range of Gleason Scores (GS). 21/61 (34.4%) samples harboured a mutation in a cell cycle pathway gene such as TP53 or RB1 and 3/61 (4.9%) in a DNA repair gene such as ATM. 10/61 (16.5%) of samples harboured a mutation in a gene associated with the Wnt pathway such as APC or CTNNB1. 14/61 (23.0%) of samples analysed had a mutation in a gene commonly associated with the PI3K pathway such as PTEN or AKT1. 5/61 (8.2%) had a mutation in a gene associated with the MAPK pathway such as KRAS. IHC profiles were analysed on 317 prostate samples: 73 normal and 244 cancers. There was greater expression of markers associated with Wnt, PI3K and MAPK signalling pathways in prostate cancer samples when compared to normal samples. There was greater expression in high-risk GSs with some markers associated with biochemical recurrence following RRP. Furthermore, we were able to separate low-and high-risk GS samples based on molecular profiles using markers of the Wnt, PI3K and MAPK and principle components analysis.
CONCLUSIONS: Targeted NGS and IHC can identify recurrent mutations and signalling pathway aberrations within primary prostate cancer samples, which have potential to be targeted and used in routine clinical practice. In addition, the molecular signatures of low-and highrisk are different and can be separated using a combination of markers and IHC. This finding could explain the marked difference in the behaviours of these tumours types.
Source of Funding: The Urology Foundation

PD33-05 TARGETED NEXT GENERATION SEQUENCING TO CHARACTERIZE MAGNETIC RESONANCE IMAGING VISIBLE AND INVISIBLE PROSTATE CANCER: BIOLOGICAL INSIGHTS AND THERAPEUTIC IMPLICATIONS
Simpa Salami, Daniel Hovelson, Aaron Udager, Matthew Lee*, Nicole Curci, Jeremy Kaplan, Arvin George, Matthew Davenport, Scott Tomlins, Ganesh Palapattu, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: While multiparametric magnetic resonance imaging (mpMRI) of the prostate has improved disease detection, up to 20% of patients with negative mpMRI harbor high grade prostate cancer (PCa). In this study, we sought to characterize and compare the molecular profiles of mpMRI visible and invisible PCa.
METHODS: Patients who underwent mpMRI prior to radical prostatectomy were identified for this IRB-approved study. mpMRI for each patient was reviewed by a radiologist with expertise in prostate mpMRI and histopathology reviewed by a genitourinary pathologist. Whole-mount histopathology was co-registered with axial mpMRI images. DNA and RNA were co-isolated from all tumor foci pre-identified on formalin-fixed paraffin-embedded specimens. High depth, targeted DNA and RNA next generation sequencing was performed to characterize the molecular profile of each tumor focus using the Oncomine Comprehensive Panel (DNA sequencing) and a custom targeted RNAseq panel assessing PCa relevant genes.
RESULTS: A total of 26 primary tumor foci from 10 patients were analyzed. The median number of PCa foci was 3. Of the 14 (54%) invisible lesions on mpMRI, 5 (36%) were Gleason 3+4¼7 (Table 1) . We detected high-confidence prioritized genetic mutations in 54% (14/ 26) of tumor foci, 43% (6/14) of which were in mpMRI-invisible lesions. Additionally, 64% (9/14) of lesions exhibiting prioritized mutations were Gleason 7. Notable point mutations were in APC, AR, ARID1B, ATM, ATRX, BRCA2, FAT1, MAP3K1, NF1, SPEN, SPOP, TP53, and a frameshift mutation was detected in SOX2. The expression profile of mpMRI visible and invisible lesions were similar (Figure 1) . CONCLUSIONS: We found no significant difference in the molecular profile of visible and invisible cancer foci on mpMRI. However, 36% of mpMRI invisible lesions exhibited biologically significant mutations. More work is needed to further characterize the molecular basis for mpMRI prostate cancer visibility.
Source of Funding: None
PD33-06 MCAM SUPPORTS THE AGGRESSIVE PHENOTYPE IN HUMAN PROSTATE CANCER
Eugenio Zoni, Letizia Astrologo, Bern, Switzerland; Janine Melsen, Leiden, Netherlands; Irena Klima, Joel Grosjean, Bern, Switzerland; Gabri van der Pluijm, Leiden, Netherlands; Marco G. Cecchini, Marianna Kruithof-de Julio*, George N. Thalmann, Bern, Switzerland INTRODUCTION AND OBJECTIVES: Prostate Cancer (PCa) is the most common cancer in males and the second leading cause of death from cancer in men. When PCa progress from localized disease to castration resistance, the formation of incurable metastases, primarily in the bone, is almost inevitable. Therefore, understanding the factors that regulate homing and survival of metastatic cancer cells in the bone is important for the identification of new therapeutic targets. High MCAM expression has been detected in the stroma of lytic and blastic lesions in preclinical models of PCa bone metastasis. The objective of this study is to characterize the role of MCAM in the maintenance of the aggressive phenotype in human PCa. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e595
